Drugs / REMIDEVIR
REMIDEVIR
Trials 10 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 19 trials | ||||||
| Phase 1 | NCT06328400 | Mar → May 2024 | respiratory syncytial virus infectious disease | Vigonvita Life Sciences | Completed | No outcome recorded |
| Phase 1 | NCT06005714 | Aug → Oct 2023 | — | Shanghai Vinnerna Biosciences Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT06093230 | Jul → Aug 2023 | liver disorder | Shanghai Vinnerna Biosciences Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT06093308 | Jul → Aug 2023 | — | Shanghai Vinnerna Biosciences Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT05932459 | Jul → Sep 2023 | — | Vigonvita Life Sciences | Completed | No outcome recorded |
| Phase 1 | NCT05895812 | May → Aug 2023 | — | Shanghai Vinnerna Biosciences Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT05221138 | Dec 2021 → Jan 2022 | — | Vigonvita Life Sciences | Completed | No outcome recorded |
| Phase 1 | NCT05201690 | Dec 2021 → Jan 2022 | — | Vigonvita Life Sciences | Completed | No outcome recorded |
| Phase 1 | NCT05227768 | Nov 2021 → Jan 2022 | — | Vigonvita Life Sciences | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT06206720 | Jan 2024 → Jun 2025 | respiratory syncytial virus infectious disease | Vigonvita Life Sciences | Completed | No outcome recorded |
Evidence & citations 11 cited values
Every value below carries the sentence it was read from. 11 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | REMIDEVIR | ChEMBL registry synonym — accepted as the source's own label CHEMBL4876167 ↗ |
| Known as | Deuremidevir | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06093308 ↗ |
| Known as | Deuremidevir Hydrobromide | “Deuremidevir Hydrobromide for Suspension will be orally administered at the dosing levels of 15 mg/kg BID, 20 mg/kg BID, or 20 mg/kg TID for five days according to the weight...” NCT06206720 ↗ |
| Known as | Deuremidevir Hydrobromide for Suspension | “Deuremidevir Hydrobromide for Suspension 900mg, orally, Q12h, 5.5 days” NCT06328400 ↗ |
| Known as | Deuremidevir Hydrobromide Tablets | “Drug: Deuremidevir Hydrobromide Tablets” NCT05895812 ↗ |
| Known as | Mindeudesivir | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06005714 ↗ |
| Known as | Mindvy | “VV116 (Mindvy, JT001) is a deuterated oral derivative of remdesivir hydrobromide developed for the treatment of COVID-19.” PMID 41733177 ↗ Feb 2026 |
| Known as | VV-116 FREE BASE | ChEMBL registry synonym — accepted as the source's own label CHEMBL4876167 ↗ |
| Known as | VV116 | “VV116 (Mindvy, JT001) is a deuterated oral derivative of remdesivir hydrobromide developed for the treatment of COVID-19.” PMID 41733177 ↗ Feb 2026 |
| Modality | Small molecule | — CHEMBL4876167 ↗ |
| Route | Oral | “Drug: VV116 9 subjects will receive VV116 200 mg, orally, QD12h, 5.5 days ;” NCT05201690 ↗ |